Live Breaking News & Updates on Guselkumab provides sustained improvements in health

New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with.

Canada , Washington , United-states , Japan , University-of-washington , Spring-house , British-columbia , Horsham , Saskatchewan , Seattle , Donvitot-creakyjoints , Terence-rooney